Literature DB >> 10423119

Cost benefit of treating hypertension.

B Jönsson1, M Johannesson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10423119     DOI： 10.3109/10641969909061026

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN： 1064-1963            Impact factor:   1.749


× No keyword cloud information.
  3 in total

1.  Comparative cost effectiveness of angiotensin II receptor blockers in a US managed care setting: olmesartan medoxomil compared with losartan, valsartan, and irbesartan.

Authors:  W Robert Simons
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

Review 2.  Economics of antihypertensive therapy in the elderly.

Authors:  E C Dunn; R E Small
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Epidemiology of essential hypertension: the role of genetic polymorphism.

Authors:  V Romano-Spica; M Mettimano; A Ianni; M L Specchia; G Ricciardi; L Savi
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.